Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/9635
Title: | Surrogate end points: hopes and perils | Authors: | ALONSO ABAD, Ariel MOLENBERGHS, Geert |
Issue Date: | 2008 | Source: | Expert Review of Pharmacoeconomics & Outcomes Research, 8(3). p. 255-259 | Abstract: | In recent years, the cost of drug development has increased the demands on efficiency in the selection of suitable drug candidates; surrogate end points have emerged to improve this process, hoping that they can help reduce duration and cost of clinical trials. Additionally, they can help in solving ethical issues when measuring the clinical end point involves the application of risky or uncomfortable medical procedures. However, the very mention of surrogate end points has always been controversial, owing in part to unfortunate historical events. As a consequence, there is growing consensus on the use of validated surrogates only. Here, we discuss some of the validation strategies that have recently been proposed and consider the future of surrogate end points in clinical research. | Keywords: | biomarker; information theory; meta-analysis; surrogate marker | Document URI: | http://hdl.handle.net/1942/9635 | ISSN: | 1473-7167 | e-ISSN: | 1744-8379 | DOI: | 10.1586/14737167.8.3.255 | Rights: | (C) 2008 Expert Reviews Ltd | Category: | A3 | Type: | Journal Contribution |
Appears in Collections: | Research publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Surrogate endpoints.pdf | Peer-reviewed author version | 235.92 kB | Adobe PDF | View/Open |
alonso2008.pdf Restricted Access | Published version | 188.76 kB | Adobe PDF | View/Open Request a copy |
SCOPUSTM
Citations
14
checked on Sep 3, 2020
Page view(s)
70
checked on Sep 7, 2022
Download(s)
236
checked on Sep 7, 2022
Google ScholarTM
Check
Altmetric
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.